MA
RNTX

Mutual Advisors’s Rein Therapeutics RNTX Stock Holding History

Mutual Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-765
Closed -$20K – 765
2020
Q3 		$20K Buy
765
+65
+9% +$1.53K ﹤0.01% 670
2020
Q2 		$17K Buy
+700
New +$11.4K ﹤0.01% 648

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Mutual Advisors's RNTX Position: Q4 2020 in Review

Mutual Advisors sold out of Rein Therapeutics (RNTX) in Q4 2020, closing a stake of 765 shares — an estimated $20K sold.

Mutual Advisors first reported a position in RNTX in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q3 2020. 30 funds tracked by Wall St. Rank hold RNTX as of Q4 2020.

  • Mutual Advisors reported no remaining Rein Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Mutual Advisors sold 765 Rein Therapeutics shares in Q4 2020, an estimated $20K.
  • Mutual Advisors first reported a position in Rein Therapeutics in Q2 2020 and held it in 2 quarters.
  • Mutual Advisors's Rein Therapeutics position peaked at $20K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2020.

Based on Mutual Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.